We are live on ! Find out more
DMAC icon

DiaMedica Therapeutics
DMAC

41 hedge funds and large institutions have $52.1M invested in DiaMedica Therapeutics in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

100% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 5

88% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 8

14% more funds holding

Funds holding: 36 → 41 (+5)

1.61% less ownership

Funds ownership: 31.93% → 30.32% (-1.6%)

14% less capital invested

Capital invested by funds: $60.6M → $52.1M (-$8.48M)

Holders
41
Holders Change
+5
Holders Change %
+13.89%
% of All Funds
0.72%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
10
Increased
15
Reduced
8
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$686K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$621K
3
CA
Corriente Advisors
Texas
+$592K
4
JAMONY
Jacob Asset Management of New York
California
+$420K
5
Renaissance Technologies
Renaissance Technologies
New York
+$371K

Top Sellers

Rank Fund Capital Flow
1
GPCM
Granite Point Capital Management
Massachusetts
-$3.39M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.31M
3
SSA
Schonfeld Strategic Advisors
New York
-$671K
4
Northern Trust
Northern Trust
Illinois
-$336K
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$190K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Stonepine Capital Management
Oregon
$9.36M +$686K +73,409 +8%
CA
2
Corriente Advisors
Texas
$7.96M +$592K +63,328 +8%
Vanguard Group
3
Vanguard Group
Pennsylvania
$7.74M +$621K +66,415 +9%
MHP
4
Manatuck Hill Partners
Connecticut
$5.22M -$9.34K -1,000 -0.2%
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$5.05M -$2.31M -247,750 -31%
IC
6
Ikarian Capital
Texas
$3.8M – – –
JAMONY
7
Jacob Asset Management of New York
California
$1.69M +$420K +45,000 +32%
GPCM
8
Granite Point Capital Management
Massachusetts
$1.69M -$3.39M -362,475 -66%
Renaissance Technologies
9
Renaissance Technologies
New York
$1.4M +$371K +39,700 +35%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$1.18M +$231K +24,769 +24%
EI
11
EAM Investors
California
$990K -$16.4K -1,753 -2%
Bank of Montreal
12
Bank of Montreal
Ontario, Canada
$982K +$212K +22,642 +28%
Northern Trust
13
Northern Trust
Illinois
$778K -$336K -35,963 -30%
Marshall Wace
14
Marshall Wace
United Kingdom
$695K +$150K +16,096 +27%
Millennium Management
15
Millennium Management
New York
$643K +$275K +29,420 +72%
BlackRock
16
BlackRock
New York
$551K +$41K +4,384 +8%
CLG
17
Cooperman Leon G
$458K +$187K +20,000 +67%
BFM
18
Boothbay Fund Management
New York
$426K – – –
Bank of New York Mellon
19
Bank of New York Mellon
New York
$371K -$21.8K -2,329 -5%
Squarepoint
20
Squarepoint
New York
$325K +$332K +35,536 New
Citadel Advisors
21
Citadel Advisors
Florida
$189K +$192K +20,601 New
Morgan Stanley
22
Morgan Stanley
New York
$178K -$11.5K -1,235 -6%
Two Sigma Advisers
23
Two Sigma Advisers
New York
$98K +$100K +10,700 New
PFGIA
24
Patriot Financial Group Insurance Agency
Massachusetts
$84K +$86K +9,203 New
FDCDDQ
25
Federation des caisses Desjardins du Quebec
Quebec, Canada
$55.2K – – –
1
2

DMAC Hedge Fund Activity: Q1 2021 in Review

41 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q1 2021, worth a combined $52.1M — down 14% from $60.6M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new DMAC positions and 5 closed out — a net gain of 5 holders — while 15 added to existing stakes and 8 trimmed.

The largest buyer was Stonepine Capital Management, adding an estimated $686K. The largest seller was Granite Point Capital Management, cutting an estimated $3.39M.

  • 41 institutional investors held DiaMedica Therapeutics (DMAC) as of Q1 2021, up from 36 in Q4 2020.
  • Funds reported $52.1M of DiaMedica Therapeutics stock for Q1 2021, down 14% quarter-over-quarter.
  • 10 funds opened new DiaMedica Therapeutics positions in Q1 2021 and 5 closed out, a net change of +5 holders.
  • The largest DiaMedica Therapeutics buyer in Q1 2021 was Stonepine Capital Management, an estimated $686K added.
  • The largest DiaMedica Therapeutics seller in Q1 2021 was Granite Point Capital Management, an estimated $3.39M sold.

Based on aggregated 13F filings for Q1 2021.